Osteoporosis International

, Volume 17, Issue 5, pp 716–723 | Cite as

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial

  • W. F. Lems
  • M. C. Lodder
  • P. Lips
  • J. W. J. Bijlsma
  • P. Geusens
  • N. Schrameijer
  • C. M. van de Ven
  • B. A. C. Dijkmans
Original Article



Alendronate has been described to have a bone-sparing effect in patients treated with moderate and high dosages of prednisone for heterogeneous diseases, however no data are available on groups of patients with the same underlying diseases who receive chronic low-dose prednisone treatment. The objective of the investigation reported here was, therefore, to study the effect of alendronate on bone mineral density (BMD) of the lumbar spine and hips in patients with rheumatoid arthritis (RA) who are on chronic low-dose prednisone treatment.


A total of 163 patients with RA, according to the ACR-criteria, were enrolled in a double-blind, placebo-controlled trial. The patients were treated with low-dose prednisone (≤10 mg/day) for at least 3 months. The patients were randomized to receive daily doses of alendronate or placebo: men and premenopausal women received 5 mg alendronate (or placebo) daily; postmenopausal women received 10 mg alendronate (or placebo) daily. All patients received daily calcium (500 mg, or 1000 mg, depending on baseline dietary calcium intake) and vitamin D3 (400 IU) supplementation. BMD of the lumbar spine (L1–L4) and the (total) hip was measured at baseline and after 6 and 12 months. The primary endpoint was change in BMD of the lumbar spine after 12 months (ITT). At baseline and after 3 and 12 months, serum bone-specific alkaline phosphatase (BAP) and urinary excretion of N-telopeptide (NTX) were measured. Radiographs of the thoracic and lumbar spine were made at baseline and after 12 months and subsequently scored for vertebral deformities.


The groups were comparable at baseline in age, gender, daily dosage of prednisone, BMD at the spine and the hip and markers of bone turnover, while the number of patients with prevalent vertebral deformities was slightly higher in the alendronate-treated patients (54% versus 39%, not significant). After 12 months, BMD at the lumbar spine had increased by 3.7% in the alendronate-treated patients and decreased by –1.0% in the placebo-treated patients (p<0.0001); at the hip, the changes were +1.0% and –0.1%, respectively (not significant). After 3 months, serum BAP had decreased by 16.9% in the alendronate group versus 3.3% in the placebo group (p=0.0005), while urinary NTX had decreased by 46.4% in the alendronate group versus 12.1% in the placebo group (p<0.0001). After 12 months, no statistically significant difference was found between the groups with respect to number of patients with incident vertebral or non-vertebral fractures. Adverse effects were relatively common in these patients with severe RA: adverse effects were observed in 68% of the alendronate-treated patients and in 73% of the placebo patients (not significant), while serious adverse events were observed in 13% and 17%, respectively (not significant).


We observed a favourable effect of alendronate on the BMD of the lumbar spine and on the markers of bone turnover in patients with RA treated with low-dose prednisone. These data support the conclusion that the prescribing of alendronate is not only beneficial in patients treated with high-dose prednisone but also in RA patients chronically treated with low-dose prednisone.


Alendronate Bone mineral density Prednisone Rheumatoid arthritis 



This trial was performed with the help of the following rheumatologists, all participants of the Osteoporosis Working Group of the Dutch Society for Rheumatology (chairperson: W.F. Lems): M.H.M. Aarts (de Weezenlanden, Zwolle), C.F. Allaart (Leiden University Medical Centre), F. Eggelmeijer (Gelre Ziekenhuizen, Apeldoorn), H. van de Leeden (Dordrecht), H.H.M.L. Houben (Atrium Medisch Centrum, Heerlen), J.D. Moolenburgh (Medisch Centrum Alkmaar), R.N.J. de Nijs (University Medical Centre, Utrecht), H.H. Nuver-Zwart (Deventer Ziekenhuis), P.L.M. van Ooijen (Jeroen Bosch Ziekenhuis, Den Bosch), H.C. van Paassen (St. Franciscus Gasthuis, Rotterdam), G. van Veen (Helmond), M.L. Westedt (Bronovo Ziekenhuis, Den Haag).


  1. 1.
    Lukert BP, Raisz LG (1990) Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Int Med 112:352–364PubMedGoogle Scholar
  2. 2.
    Staa TP van, Leufkens HGM, Abenhaim L et al (2002) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:1993–2000Google Scholar
  3. 3.
    Manologas SC, Weinstein RS (1999) New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061–1066PubMedCrossRefGoogle Scholar
  4. 4.
    Canalis E (2003) Mechanisms of glucocorticoid-induced osteoporosis. Curr Opinion Rheumatol 15:454–457CrossRefGoogle Scholar
  5. 5.
    Haugeberg G, Orstavik R, Kvien TK (2003) Effects of rheumatoid arthritis on bone. Curr Opinion Rheumatol 15:469–475CrossRefGoogle Scholar
  6. 6.
    Bijlsma JW, Everdingen AA van, Huisman M et al (2002) Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann NY Acad Sci 966:82–90PubMedCrossRefGoogle Scholar
  7. 7.
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Engl J Med 334:292–299CrossRefGoogle Scholar
  8. 8.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:2309–2318CrossRefPubMedGoogle Scholar
  9. 9.
    Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture rate in patients receiving glucocorticoids. Arthritis Rheum 44:200–211CrossRefGoogle Scholar
  10. 10.
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF et al (2000) Effects of risedronate treatment on bone density and vertebral fracture rate in patients with corticosteroid therapy. Calcif Tissue Int 67:277–285CrossRefPubMedGoogle Scholar
  11. 11.
    Arnett FC, Edworthy SM, Bloch DA, Mc Shane DJ, Fries JR, Cooper NS et al (1998) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefGoogle Scholar
  12. 12.
    Genant HK, Jergas M, Palermo et al (1996) Comparison of semiquantitative techniques and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996PubMedCrossRefGoogle Scholar
  13. 13.
    Homik JE, Cranney A, Shea B, Tugwell P, Wells G, Adachi JD, et al (1999) A meta-analysis on the use of bisphosphonates in corticosteroid-induced osteoporosis. J Rheumatol 26:1148–1157PubMedGoogle Scholar
  14. 14.
    American College of Rheumatology AdHoc Committee on Glucocorticoid-Induced Osteoporosis 2001 (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503CrossRefGoogle Scholar
  15. 15.
    Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy for the management of corticosteroid-induced osteoporosis: a meta regression. J Bone Miner Res 17:1512–1516PubMedCrossRefGoogle Scholar
  16. 16.
    Kirwan JR (1995) The Arthritis and Rheumatism Council low dose glucocorticoid study group. The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333:142–146CrossRefPubMedGoogle Scholar
  17. 17.
    Everdingen AA van, Jacobs JWJ, Siewertz van Reesema DR et al (2002) Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects: a randomized, double blind, placebo-controlled trial. Ann Int Med 136:1–12PubMedGoogle Scholar
  18. 18.
    Bijlsma JWJ, Boers M, Saag KG, Furst DE (2003) Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis 62:1033–1037CrossRefPubMedGoogle Scholar
  19. 19.
    Buckley LM, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemare S et al (1996) Calcium and vitamin D supplementation prevents bone loss in patients with rheumatoid arthritis: a randomized, double blind placebo controlled trial. Ann Int Med 125:961–966PubMedGoogle Scholar
  20. 20.
    Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson et al (2002) Alendronate. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:508–516CrossRefPubMedGoogle Scholar
  21. 21.
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, Lacroix AZ et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289CrossRefPubMedGoogle Scholar
  22. 22.
    Ross PD, Davis JW, Epstein RS, Wasnich RD (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Int Med 114:919–923PubMedGoogle Scholar

Copyright information

© International Osteoroposis Foundation and National Osteoroposis Foundation 2006

Authors and Affiliations

  • W. F. Lems
    • 1
    • 2
  • M. C. Lodder
    • 1
  • P. Lips
    • 3
  • J. W. J. Bijlsma
    • 4
  • P. Geusens
    • 5
    • 6
  • N. Schrameijer
    • 7
  • C. M. van de Ven
    • 7
  • B. A. C. Dijkmans
    • 1
    • 2
  1. 1.VU University Medical CentreDepartment of RheumatologyAmsterdamThe Netherlands
  2. 2.Slotervaart HospitalDepartment of RheumatologyAmsterdamThe Netherlands
  3. 3.VU University Medical CentreDepartment of EndocrinologyAmsterdamThe Netherlands
  4. 4.University Medical Centre UtrechtDepartment of RheumatologyUtrechtThe Netherlands
  5. 5.Academic Hospital MaastrichtDepartment of RheumatologyMaastrichtThe Netherlands
  6. 6.Limburgs Universitair CentrumDepartment of RheumatologyDiepenbeekBelgium
  7. 7.MSDHaarlemThe Netherlands

Personalised recommendations